Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 134 Cr.
- Current Price ₹ 84.8
- High / Low ₹ 145 / 65.5
- Stock P/E 20.0
- Book Value ₹ 94.1
- Dividend Yield 0.00 %
- ROCE 8.22 %
- ROE 4.72 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.90 times its book value
Cons
- Company has low interest coverage ratio.
- Debtor days have increased from 36.2 to 44.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 369 | 318 | |
| 351 | 282 | |
| Operating Profit | 17 | 36 |
| OPM % | 5% | 11% |
| 0 | 0 | |
| Interest | 14 | 15 |
| Depreciation | 15 | 17 |
| Profit before tax | -11 | 5 |
| Tax % | -18% | -41% |
| -9 | 7 | |
| EPS in Rs | -5.73 | 4.25 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 175% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 5% |
| 3 Years: | -16% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| Reserves | 120 | 133 |
| 106 | 89 | |
| 92 | 128 | |
| Total Liabilities | 334 | 366 |
| 148 | 165 | |
| CWIP | 8 | 0 |
| Investments | 0 | 0 |
| 178 | 201 | |
| Total Assets | 334 | 366 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 43 | |
| -12 | -19 | |
| 5 | -22 | |
| Net Cash Flow | -3 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 28 | 45 |
| Inventory Days | 185 | 303 |
| Days Payable | 99 | 199 |
| Cash Conversion Cycle | 113 | 149 |
| Working Capital Days | 90 | 94 |
| ROCE % | 8% |
Documents
Announcements
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025 till 48 hours after June 30, 2025 quarterly results.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report for FY ended March 31, 2025; no major non-compliances reported.
-
Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 17Th May, 2025 Inter- Alia To Approve Audited Financial Results For The Quarter And Year Ended 31St March, 2025.
30 May - Mangalam Drugs reports FY25 audited results: Rs.692.43L standalone net profit, no audit modifications, secretarial auditor appointed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 May - Newspaper publication for Declaration of financial results for the quarter and year ended 31st March, 2025
-
Approval Of Financial Results For The Quarter And Year Ended 31St March, 2025
17 May - Approved audited financial results FY25; appointed secretarial auditor FY24; auditors gave unmodified opinion.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations